Results 101 to 110 of about 2,921 (133)

Absorbed Dose-Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [¹⁷⁷Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine. [PDF]

J Nucl Med
Hebert K, Santoro L, Monnier M, Castan F, Berkane I, Assénat E, Fersing C, Gélibert P, Pouget JP, Bardiès M, Kotzki PO, Deshayes E.   +11 more
europepmc   +1 more source

The Impact of Posttreatment Imaging in Peptide Receptor Radionuclide Therapy. [PDF]

J Nucl Med
Yadav S, Lawhn-Heath C, Paciorek A, Lindsay S, Mirro R, Bergsland EK, Hope TA.   +6 more
europepmc   +1 more source

Multiomics Mendelian randomization integrating pQTL, eQTL and mQTL data revealed BTN3A2 as a potential drug target for nephrolithiasis. [PDF]

Sci Rep
Sun S, Wang Y, Dong Q, Bi J, Fu Y.
europepmc   +1 more source

Q&A Translational Cancer Nanomedicine. [PDF]

Nat Commun
europepmc   +1 more source

Rare but not forgotten: Therapeutic advancements for rare childhood cancers. [PDF]

Mol Ther Oncol
Crane JN, Dagalakis U, Gartrell RD, Schultz KAP, Laetsch TW.   +4 more
europepmc   +1 more source

Twenty-one-year report from the Danish Health Authority Expert Advisory Panel for review of treatment of 10 000 cancer patients. [PDF]

Oncologist
Ladekarl M, Mørk ML, Albertsen ES, Nielsen D, Lassen U, Mau-Sørensen M, Nielsen CM, Jakobsen A, von der Maase H.   +8 more
europepmc   +1 more source

Gastric neuroendocrine tumors: A review of pathology and updated roadmap to surgical management. [PDF]

World J Clin Oncol
Agathis AZ, Lopez-May M, Brown C, Divino CM.   +3 more
europepmc   +1 more source